NYSE:NVOPharmaceuticals
Novo Nordisk Advances Diabetes And Obesity Portfolio As Valuation Looks Attractive
Novo Nordisk (NYSE:NVO) has expanded its partnership with Aspect Biosystems to advance cell-based treatments for diabetes.
The company has launched an oral version of Wegovy, the first FDA approved oral GLP-1 pill for obesity.
These moves broaden Novo Nordisk's diabetes pipeline and strengthen its position in obesity treatments with a non injectable option.
Novo Nordisk, trading at $62.23, sits at the center of two closely watched areas in healthcare: diabetes and obesity care. The stock is...